Levinson Adam W, Bagga Herman S, Pavlovich Christian P, Mettee Lynda Z, Ward Nicholas T, Link Richard E, Su Li-Ming
James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
J Urol. 2008 May;179(5):1818-22. doi: 10.1016/j.juro.2008.01.050. Epub 2008 Mar 18.
We assessed the effects of prostate size on long-term health related quality of life and functional outcomes after laparoscopic radical prostatectomy.
A total of 729 consecutive patients who underwent laparoscopic radical prostatectomy for localized prostate cancer were stratified by pathological prostate gland weight, including group 1--less than 35 gm, group 2--35 to 70 gm and group 3--greater than 70 gm. Urinary health related quality of life was assessed preoperatively and at regular intervals following laparoscopic radical prostatectomy using the validated Expanded Prostate Cancer Index Composite questionnaire.
A total of 613 evaluable patients were studied with a mean age of 57.7 years, a preoperative prostate specific antigen of 6.0 ng/ml, a median preoperative and postoperative Gleason score of 6, and a mean pathological gland weight of 51.3 gm (range 13.4 to 145.7). Patients with the largest glands had significantly worse baseline urinary function, as demonstrated by Expanded Prostate Cancer Index Composite urinary domain summary (p <0.001) and subscale scores, including scores for urinary bother (p <0.001), urinary irritative/obstructive (p = 0.001) and urinary incontinence (p = 0.03). Patients in group 3 also had significantly older age, a higher body mass index, longer operative time and more blood loss (each p <0.05). Despite preoperative differences and possible confounders all groups approached similar urinary health related quality of life outcomes at all time points postoperatively. At 12 months patients with the largest glands had improved Expanded Prostate Cancer Index Composite urinary irritative/obstructive and urinary bother subscale scores compared to their baseline scores (p <0.05).
In laparoscopic radical prostatectomy despite preoperative differences increasing prostatic size is not associated with delayed or worse postoperative urinary health related quality of life. Furthermore, in patients with large glands an improvement in urinary irritative/obstructive and bother symptoms from baseline may be seen 12 months postoperatively.
我们评估了前列腺大小对腹腔镜根治性前列腺切除术后长期健康相关生活质量和功能结局的影响。
共有729例因局限性前列腺癌接受腹腔镜根治性前列腺切除术的连续患者,根据病理前列腺重量进行分层,包括第1组(小于35克)、第2组(35至70克)和第3组(大于70克)。使用经过验证的扩展前列腺癌指数综合问卷,在术前以及腹腔镜根治性前列腺切除术后定期评估与泌尿健康相关的生活质量。
共研究了613例可评估患者,平均年龄57.7岁,术前前列腺特异性抗原为6.0纳克/毫升,术前和术后Gleason评分中位数为6,平均病理腺体重量为51.3克(范围13.4至145.7克)。如扩展前列腺癌指数综合泌尿领域总结(p<0.001)和子量表评分所示,腺体最大的患者基线泌尿功能明显更差,包括泌尿困扰评分(p<0.001)、泌尿刺激/梗阻评分(p = 0.001)和尿失禁评分(p = 0.03)。第3组患者年龄也明显更大,体重指数更高,手术时间更长,失血量更多(均p<0.05)。尽管存在术前差异和可能的混杂因素,但所有组在术后所有时间点的泌尿健康相关生活质量结局都接近相似。在12个月时,腺体最大的患者与基线评分相比,扩展前列腺癌指数综合泌尿刺激/梗阻和泌尿困扰子量表评分有所改善(p<0.05)。
在腹腔镜根治性前列腺切除术中,尽管存在术前差异,但前列腺大小增加与术后延迟或更差的泌尿健康相关生活质量无关。此外,对于腺体较大的患者,术后12个月可能会出现泌尿刺激/梗阻和困扰症状较基线改善的情况。